FIELD: pharmacology.
SUBSTANCE: invention relates to diaryl derivatives of the formula 1 
, or their pharmaceutically acceptable salts or isomers of formula 1, wherein A and B are independently phenyl or pyridine provided that when B is phenyl, -G-COOR7 is substituted in the para-position of phenyl and, when B is pyridine, -G-COOR7 is substituted in position 3 of pyridine, any of R1-D and R2-E may be absent, D and E are independently carbon, nitrogen, oxygen or sulfur, or represent a direct bond, and any of R1 and R2 may be absent, or R1 is a halogen, C1-C6-alkyl, optionally substituted with halogen, C3-C10-cycloalkyl, C1-C6-alkoxy, C1-C6-alkylamino, C3-C10-heterocycloalkyl or C1-C6-alkyl-C3-C10-heterocycloalkyl, C3-C10-cycloalkyl, optionally substituted by C3-C10-alkylsilanyloxy or hydroxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C10-heterocycloalkyl, optionally substituted by C1-C6-alkylamino or halogen, C1-C6-alkyl-C3-C10-heterocycloalkyl, phenyl, C3-C9-heteroaryl or C1-C6-alkyl-C5-C6-heteroaryl, R2 is hydrogen, halogen, C1-C6-alkyl, optionally substituted with halogen, C3-C10-cycloalkyl, C1-C6-alkoxy, C1-C6-alkylamino, C3-C10-heterocycloalkyl or C1-C6-alkyl-C3-C10-heterocycloalkyl, C3-C10-cycloalkyl, optionally substituted with C3-C10-alkylsilaniloxy or hydroxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C10-heterocycloalkyl, optionally substituted with C1-C6-alkylamino or halogen, C1-C6-alkyl-C3-C10-heterocycloalkyl, phenyl, C3-C9-heteroaryl or C1-C6-alkyl-C5-C6-heteroaryl and, when D and E represent nitrogen or carbon, R1 and R2 may represent two or three groups, which may be the same or different, isolated from C1-C6-alkyl or phenyl, G is -J-(CR5C6)p, where J is oxygen or sulfur, R5 and R6 independently represent hydrogen, C1-C6-alkyl or C3-C10-cycloalkyl and R5 and R6, substituted in the one and the same or different carbon atoms, may be bound producing C3-C10-cycloalkyl, R1 and R4 independently from each other may be absent depending on m and n value or independently represent hydrogen, halogen or C1-C6-alkyl, or C1-C6-alkoxy, R7 is hydrogen or C1-C6-alkyl, m and n independently represent an integral number from 0 to 5 and p is an integral number from 2 to 6, where heterocycloalkyl and heteroaryl contain at least one heteroatom, isolated from N, O, and S, to the pharmaceutical composition, containing them, and method of its production.
EFFECT: stimulates the formation of GLP-1 in the gastrointestinal tract and improves insulin resistance in the liver or muscles, effective prevention or treatment of diabetes, complications of diabetes, obesity, non-alcoholic fatty hepatosis, steatohepatitis, osteoporosis or inflammation.
6 cl, 1 tbl, 279 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIARYL DERIVATIVE AS GPR120 AGONIST | 2015 |
|
RU2683648C2 |
| NEW 2-HETEROARYL-SUBSTITUTE BENZIMIDAZOLE DERIVATIVE | 2004 |
|
RU2329261C2 |
| BRIDGED PYRIMIDINONE COMPOUNDS AND METHODS FOR PREPARATION, COMPOSITIONS AND USE THEREOF | 2021 |
|
RU2830820C1 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
| OBTAINING AND USING TRICYCLIC PYRIMIDINONE COMPOUND AND COMPOSITION THEREOF | 2021 |
|
RU2820903C1 |
| DERIVATIVES OF HETEROARYLCARBAMOYLBENZENE | 2004 |
|
RU2330030C2 |
| 2,7-SUBSTITUTED DERIVATIVES OF OCTAHYDRO-1H-[1,2-A]-PYRAZINE, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF BINDING DOPAMINE WITH DOPAMINE D RECEPTOR | 1995 |
|
RU2163239C2 |
| ANTIVIRAL COMPOUND | 2006 |
|
RU2441010C2 |
| [1,8]NAPHTHYRIDINE DERIVATIVES, USEFUL AS INHIBITORS OF HCV VIRUS REPLICATION | 2006 |
|
RU2467007C2 |
| CYCLOALKANE DERIVATIVE | 2013 |
|
RU2635354C2 |
